Baird Maintains an 'Outperform' on Optimer Pharmaceuticals (OPTR) Following Positive FDA Background Documents for Fidaxomicin
Tweet Send to a Friend
Baird maintains an 'Outperform' on Optimer Pharmaceuticals (NASDAQ: OPTR), PT $16.
Baird analyst says, "Continue to recommend purchase following positive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst says, "Continue to recommend purchase following positive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
